



AHCL/ SE/ 26 /2017-18

August 14, 2017

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting –Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)

Pursuant to the above regulations, we wish to inform that the Board of Directors of the Company at its meeting held today (**August 14, 2017**) had inter-alia approved the Un-audited Standalone Financial Results for the quarter ended June 30, 2017. The same along with the Limited Review Report issued by M/s. P.S.Subramania Iyer & Co , Chartered Accountants; Statutory Auditors of the Company is enclosed;

The Board Meeting commenced at 11.15 A.M. and concluded at 15:45P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**


(M Srinivasan)
Company Secretary & Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter ended June 30, 2017
2. Limited Review Report
3. Press Release (Highlights)

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 - 2466 9000
Fax :+91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No.: 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017



P. S. SUBRAMANIA IYER & CO.

CHARTERED ACCOUNTANTS

New No. 103, (Old No. 57/2), P. S. Sivasamy Salai, (Sullivan Garden Road), Mylapore, Chennai - 600 004.

Phone : 2499 2449 / 2499 2470

E-mail : pssco_2000@yahoo.com pssandco@gmail.com

Limited Review Report On Quarterly standalone Financial Results of AMRUTANJAN HEALTH CARE LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of
AMRUTANJAN HEALTH CARE LIMITED
CHENNAI

We have reviewed the accompanying statement of unaudited standalone financial results (the statement) of AMRUTANJAN HEALTH CARE LIMITED (the Company) for the quarter ended 30th June 2017 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 30th June 2016 including the reconciliation of profit under Ind AS of the corresponding quarter with profit reported under previous GAAP, as reported in these Financial results have been approved by company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and SEBI Circular CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.S.Subramania Iyer &Co
Chartered Accountants
FRN:004104S



V Swaminathan

V.Swaminathan
Partner
M.No.022276

Place :Chennai
Date: 14.08.2017

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.
email id : investors@amrutanjan.com; website : www.amrutanjan.com; CIN No : L24231TN1936PLC000017

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUN 2017

(Rs. In Lakhs)

SI No.	Particulars	QUARTER ENDED	
		30-Jun-17	30-Jun-16
		(unaudited)	(unaudited)
1	Revenue from operations	3,202.36	3,429.94
2	Other Income	130.18	113.59
3	Total Revenue (1+2)	3,332.55	3,543.53
4	Expenses		
	a)Cost of Material consumed	1,342.52	1,590.01
	b)Purchase of Stock-in-trade	611.63	278.31
	c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(414.08)	(327.24)
	d)Employee benefits expenses	800.03	783.30
	e)Advertisement and Selling expenses	328.89	249.61
	f)Finance Costs	14.19	5.52
	g)Depreciation and amortisation expenses	68.99	63.02
	h)Other expenses	744.43	598.48
	Total expenses	3,496.60	3,241.01
5	Profit before tax (3-4)	(164.05)	302.52
6	Tax expense (net of deferred tax)	(13.01)	91.95
7	Net profit / (Loss) after tax (5-6)	(151.04)	210.57
8	Other comprehensive income (net of tax)	-	-
9	Total Comprehensive Income (after tax)	(151.04)	210.57
10	Paid-up Equity share capital (Face Value of Rs2/- per share)	292.31	292.31
11	Earnings Per Share EPS - Rs. (Not Annualised)		
	a) Basic and diluted EPS	(1.03)	1.44

For Amrutanjan Health Care Limited

S. Sambhu Prasad

S. Sambhu Prasad

Chairman & Managing Director



Place : Chennai

Date : 14th, Aug 2017

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.
email id : investors@amrutanjan.com website : www.amrutanjan.com CIN No : L24231TN1936PLC000017
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUN 2017

(Rs. In Lakhs)

Notes

1 Segment reporting for the quarter ended Jun 30,2017

PARTICULARS	QUARTER ENDED	
	30-Jun-17	30-Jun-16
	(unaudited)	(unaudited)
1 Segment Revenue		
Net Sales		
a) O T C Products	2,291.94	2,546.31
b) Beverages	789.72	856.15
c) APMC	87.91	27.48
d) Others	32.79	-
T o t a l	3,202.36	3,429.94
Less: Inter segment revenue	-	-
Sales / Income from operations	3,202.36	3,429.94
2 Segment Results		
Profit/(Loss) Before Tax and Interest		
a) O T C Products	(165.35)	355.19
b) Beverages	(90.91)	(114.38)
c) APMC	7.71	(32.48)
d) Others	(2.06)	-
T o t a l	(250.60)	208.33
Less : i) Interest	14.19	5.52
ii) Other un-allocable expenditure net off unallocable income	(100.74)	(99.71)
Less: Exceptional items	-	-
Total Profit Before Tax	(164.05)	302.52
3 Segment Assets		
a) O T C Products	9,214.71	7,918.49
b) Beverages	1,531.89	1,291.89
c) APMC	30.09	34.77
d) Others	305.35	-
e) Unallocated	2,831.49	4,730.96
Total	13,913.53	13,976.11
4 Segment Liabilities		
a) O T C Products	1,467.25	1,969.44
b) Beverages	743.73	795.08
c) APMC	-	-
d) Others	368.38	-
e) Unallocated	-	116.39
Total	2,579.36	2,880.91

For Amrutanjan Health Care Limited





Place : Chennai

Date : 14th, Aug 2017

S.Sambhu Prasad
Chairman & Managing Director

AMRUTANAJAN HEALTH CARE LIMITED
REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE,
CHENNAI - 600 004.

email id : investors@amrutanjan.com; website : www.amrutanjan.com; CIN No :
L24231TN1936PLC000017

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUN 2017

Notes:

- 2 The Company has adopted the Indian Accounting Standards (INDAS) from April 1,2017 and these financials have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under. The date of transition to IND AS is April 1,2016. The impact of transaction has been accounted for in opening reserves and the comparative period results has been restated accordingly.
- 3 The above mentioned unaudited financial results where reviewed by the audit committee and approved by the board of Directors at their meeting held on 14th Aug 2017.
- 4 As per IND AS 108, the company has identified OTC, Food & Beverages and APMC as reportable segments.
- 5 The current period result includes performance of Amrutanjan Pharmaessence Private Limited., a wholly owned subsidiary which got merged with Amrutanjan Health Care Limited w.e.f.1-Jul-2016 in terms of the scheme of amalgamation sanctioned by National Company Law Tribunal,Chennai as per Order dated 13th July 2017.
- 6 Reconciliation of net profit previously reported on account of transition from the previous Indian GAAP to IND AS for the quarter ended June 30,2016 is as under :

Particulars	Quarter ended Jun 30,2016
	Unaudited (Rs. in Lakhs)
Net profit under IGAAP	210.57
Add/(less)	-
Net profit under IND AS	210.57

- 7 The previous period's figures have been regrouped to confirm to current period's required reclassification.

For Amrutanjan Health Care Limited.



S.Sambhu Prasad
Chairman & Managing Director



Place : Chennai
Date : 14th August, 2017.

Financial Highlights of Q1 / 2017-18

- Gross sales of the Company have decreased from Rs. 34.29 cr. to Rs. 32.02 Cr.
- Profit Before Tax is negative at Rs. 1.64 Cr. against Rs. 3.02. Cr. of positive during the same period of previous year
- 12 % drop in sales in OTC business resulted in 20 % drop in profit (at gross margin level) due to increase in material cost and the product mix.

Reconciliation between profit of Q1 of 2017-18 and Q1 of 2016-17

	Rs. In Crores
Drop in Head Range	(2.60)
Material Cost	(0.60)
Freight	(0.70)
ATL	(0.40)
BTL	(0.80)
Admn Cost & Ex. Duty	(0.53)
Total Impact -Loss	(5.63)
Gain in Margin from additional sales of COMFY	0.98
Net Impact in profitability	(4.65)

- We had double digit secondary growth in April and May. But GST destocking by trade resulted in drop in secondary sales during the month of June.
- High channel inventory in FY 16-17 due to demonetisation also added to this drop.
- We had the highest channel inventory in last three years.
- **We find the underlying brand and business fundamentals to be strong and foresee a bounce to growth in the second half of the year.**

OTC

- Gross margin has decreased from 57.58 % of previous year same period to 51.02% and it was contributed by high menthol price, packaging material prices and product mix.
- Gross sales of OTC have decreased from Rs. 27.03 cr. To Rs. 24.38 Cr. (12 % drop in Volume due to transmission to GST regime)
- Sanitary Napkin –COMFY sales has grown from Rs. 0.82 Cr (Q1 of 2016-17) to Rs. 3.43 Cr. (Q1 of 2017-18)

Beverages

- The losses from this division have come down by around Rs. 25 lakhs compared to that of same period of last year.

APMC

- The Revenue for the period YTD June 2017 is Rs. 87 Lakhs against the revenue of Rs. 27 lakhs during the same period of last year.
- The division is at breakeven level showing a profit of Rs. 7.7 Lakhs